Literature DB >> 33346078

Synergistic effect of two antimicrobial peptides, Nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates.

Abolfazl Jahangiri1, Alireza Neshani2, Seyed Ali Mirhosseini1, Kiarash Ghazvini3, Hosna Zare4, Hamid Sedighian5.   

Abstract

BACKGROUND: Infections caused by drug-resistant strains of Acinetobacter baumannii and Pseudomonas aeruginosa are now a global problem that requires the immediate development of new antimicrobial drugs. Combination therapy and using antimicrobial peptides are two strategies with high potential to solve this issue. By these strategies, this study aimed to determine the antimicrobial effect of Nisin and P10 antimicrobial peptides on extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates, and investigate the most effective combination of an antimicrobial peptide with an antibiotic.
MATERIAL AND METHODS: This study was performed on five resistant clinical isolates and one standard strain for each kind of bacterium. First, the minimum inhibitory concentrations of two antimicrobial peptides (Nisin and P10) and five common antibiotics for the treatment of Gram-negative bacteria (ceftazidime, tobramycin, ciprofloxacin, doripenem, and colistin) was determined using Scanner-Assisted Colorimetric MIC Method. Then, the combination effect of P10+Nisin, P10+antibiotics, Nisin + antibiotics was investigated using checkerboard method.
RESULTS: The MIC value of Nisin and P10 against studied pathogens were 64-256 and 8-32 μg/ml, respectively. P10+Nisin combination showed synergistic effect against standard strains and additive effect against drug-resistant clinical isolates. It was also found that the combination effect of P10+ceftazidim, P10+doripenem, and Nisin + colistin was synergistic in most cases. Nisin + tobramycin combination showed synergistic effect in exposure to standard strains, while the synergy is strain-dependent against drug-resistant clinical isolates.
CONCLUSION: In conclusion, the synergism of Nisin + colistin and P10+ceftazidime/doripenem could be of great therapeutic value as antimicrobial drugs against infections caused by colistin-resistant P.aeruginosa and XDR A. baumannii.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Antimicrobial peptides; Nisin; P10; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2020        PMID: 33346078     DOI: 10.1016/j.micpath.2020.104700

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  8 in total

1.  A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.

Authors:  Mohammad Reza Rahbar; Shaden M H Mubarak; Anahita Hessami; Bahman Khalesi; Navid Pourzardosht; Saeed Khalili; Kobra Ahmadi Zanoos; Abolfazl Jahangiri
Journal:  Sci Rep       Date:  2022-06-27       Impact factor: 4.996

2.  In Vitro Activity of Peptide Antibiotics in Combination With Other Antimicrobials on Extensively Drug-Resistant Acinetobacter baumannii in the Planktonic and Biofilm Cell.

Authors:  Qianlin Meng; Fei Lin; Baodong Ling
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

Review 3.  Rescuing humanity by antimicrobial peptides against colistin-resistant bacteria.

Authors:  Majid Taati Moghadam; Ali Mojtahedi; Mehrdad Moosazadeh Moghaddam; Mahdi Fasihi-Ramandi; Reza Mirnejad
Journal:  Appl Microbiol Biotechnol       Date:  2022-05-23       Impact factor: 5.560

Review 4.  Insect antimicrobial peptides: potential weapons to counteract the antibiotic resistance.

Authors:  M D Manniello; A Moretta; R Salvia; C Scieuzo; D Lucchetti; H Vogel; A Sgambato; P Falabella
Journal:  Cell Mol Life Sci       Date:  2021-02-17       Impact factor: 9.261

5.  The Antimicrobial Peptide Esc(1-21) Synergizes with Colistin in Inhibiting the Growth and in Killing Multidrug Resistant Acinetobacter baumannii Strains.

Authors:  Federica Sacco; Camilla Bitossi; Bruno Casciaro; Maria Rosa Loffredo; Guendalina Fabiano; Luisa Torrini; Flavia Raponi; Giammarco Raponi; Maria Luisa Mangoni
Journal:  Antibiotics (Basel)       Date:  2022-02-11

6.  Anti-Acinetobacter baumannii single-chain variable fragments show direct bactericidal activity.

Authors:  Eilnaz Basardeh; Somayeh Piri-Gavgani; Behnoush Soltanmohammadi; Mostafa Ghanei; Mir Davood Omrani; Mahdieh Soezi; Mohammad Ali Shokrgozar; Masoumeh Azizi; Abolfazl Fateh; Farzam Vaziri; Seyed Davar Siadat; Zahra Sharifzadeh; Fatemeh Rahimi-Jamnani
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532

Review 7.  Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria.

Authors:  Cesar Augusto Roque-Borda; Patricia Bento da Silva; Mosar Corrêa Rodrigues; Ricardo Bentes Azevedo; Leonardo Di Filippo; Jonatas L Duarte; Marlus Chorilli; Eduardo Festozo Vicente; Fernando Rogério Pavan
Journal:  Pharmaceutics       Date:  2021-05-21       Impact factor: 6.321

8.  Combination of Amphiphilic Cyclic Peptide [R4W4] and Levofloxacin against Multidrug-Resistant Bacteria.

Authors:  Muhammad Imran Sajid; Sandeep Lohan; Shun Kato; Rakesh Kumar Tiwari
Journal:  Antibiotics (Basel)       Date:  2022-03-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.